» Articles » PMID: 22770475

Study of Chemoresistant CD133+ Cancer Stem Cells from Human Glioblastoma Cell Line U138MG Using Multiple Assays

Overview
Journal Cell Biol Int
Specialty Cell Biology
Date 2012 Jul 10
PMID 22770475
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma is one of the most common malignant tumours in adults, with an average life expectancy of less than 1 year. The high mortality of glioblastomas is attributed to its resistance to conventional chemotherapeutic agents. Numerous studies have established the presence of a cancer stem population within glioblastomas. These CSC (cancer stem cell) populations express the cell-surface marker, CD133, and are tumorigenic and chemoresistant. Hence, CSCs make a potential target for anticancer therapies. We have focused on techniques that can reliably identify and isolate a viable CSC population, and studied their chemoresistant attributes. We show the presence of a CSC population within a slowly proliferating glioblastoma cell line, U138MG. An improvised neurosphere enrichment culture technique was developed for the isolation of CSC population. Stem cell neurospheres obtained by this protocol maintained their viability for several weeks, and could be redispersed for deriving colony-forming units and secondary spheres from single-cell suspensions. RT-PCR (reverse transcription-PCR), cell surface localization by immunofluorescence and enumeration by FACS analysis showed that the sphere cultures of U138MG grown on agarose-coated plates had elevated CD133 levels. Drug sensitivity assays indicated that these enriched spheres were more resistant to drug treatment than their non-CSC controls. Drug-resistant CSC had an increased expression of ABC (ATP-binding-cassette) drug transporters, such as ABCC2, ABCC4, ABCG2 and p-glycoprotein, indicative of their role in the resistance mechanisms. These studies will facilitate the development of in vitro assays for the sparse CSC population and strategies for improved treatment regimens for glioblastomas.

Citing Articles

Molecular pathways in glioblastoma-derived stem cells to identify effective drug agents: A bioinformatics study.

Mirzaei T, Sheikholeslami S, Bereimipour A, Jalili A, Zali A, Sharbati S J Family Med Prim Care. 2022; 11(6):2856-2864.

PMID: 36119333 PMC: 9480797. DOI: 10.4103/jfmpc.jfmpc_1436_21.


SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial-mesenchymal transition by β-catenin and Beclin1/autophagy signaling in colorectal cancer.

Zhu Y, Huang S, Chen S, Chen J, Wang Z, Wang Y Cell Death Dis. 2021; 12(5):449.

PMID: 33953166 PMC: 8100126. DOI: 10.1038/s41419-021-03733-5.


Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival.

Bien-Moller S, Balz E, Herzog S, Plantera L, Vogelgesang S, Weitmann K Stem Cells Int. 2018; 2018:9628289.

PMID: 29535786 PMC: 5822829. DOI: 10.1155/2018/9628289.


Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.

Zhang X, Liu X, Zhou W, Yang M, Ding Y, Wang Q Cell Death Dis. 2018; 9(2):190.

PMID: 29416017 PMC: 5833824. DOI: 10.1038/s41419-017-0251-9.


Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL.

Lee S, Hyun S, Kim H, Kang C, Kim S Oncol Res. 2017; 24(6):495-509.

PMID: 28281970 PMC: 7838688. DOI: 10.3727/096504016X14685034103950.